Back to search

Merck Serono Limited

22 contracts won£5,035,015,147 total value

Every public sector contract Merck Serono Limited has won, with the buyer, value and end date for each. When these contracts approach their end date they usually return to the market. Business predicts when, follows Merck Serono Limited for you, and alerts you the moment a renewal goes live.

Where they win

The sectors, tender types and buyers where Merck Serono Limited wins most often.

See every live NHS tenders and find your next contract before they do.

See all NHS buyers and UK contract awards.

Sectors

Healthcare & Medical22

Top Buyers

NHS England
10 contracts
£4,967,658,269
The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
4 contracts
£39,071,194
The NHS Commissioning Board (operating under the name of NHS England)
2 contracts
IKK classic
1 contract
GWQ ServicePlus AG
1 contract
AOK Nordwest – Die Gesundheitskasse
1 contract
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
1 contract
£15,300,000
The Common Services Industry (more commonly known as NHS National Services Scotland) ("NSS")
1 contract
£12,985,684

Awards(22)

Sort:

NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National

NHS England
Runcorn
£261,895,933
Awarded 25 Jun 2025
Ends 31 Aug 2027

NHS Framework Agreement for Branded Medicines - Proprietary Category Tender

NHS England
Runcorn
£1,241,520,444
Awarded 24 Mar 2025
Ends 30 Apr 2029

NP49024 Growth Hormone

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Edinburgh
£15,300,000
Awarded 7 Jan 2025

NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024

NHS England
Runcorn
£1,009,500,000
Awarded 5 Apr 2024
Ends 30 Apr 2028

NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024

NHS England
Runcorn
£688,010,000
Awarded 26 Jan 2024
Ends 31 Aug 2026

NHS South of England Branded Medicines - Tranche A - September 2023

NHS England
Runcorn
£249,832,000
Awarded 18 Jul 2023
Ends 31 Aug 2025

NHS London Branded Medicines - Tranche B - September 2023

NHS England
Runcorn
£231,083,000
Awarded 14 Jul 2023
Ends 31 Aug 2025

NHS Framework Agreement-Branded Medicines - National Proprietary Pharmaceuticals

NHS England
Runcorn
£304,504,000
Awarded 24 Apr 2023
Ends 30 Apr 2025

NHS Midland & East Branded Medicines, Tranche B & Annual Tranche

NHS England
Runcorn
£480,429,000
Awarded 13 Feb 2023
Ends 28 Feb 2025

NHS Framework for North of England Branded Medicines Tranche A & Annual Tranche

NHS England
RUNCORN
£261,970,000
Awarded 8 Feb 2023
Ends 28 Feb 2025

NP47822 Multiple Sclerosis Medicines

The Common Services Industry (more commonly known as NHS National Services Scotland) ("NSS")
Edinburgh
£12,985,684
Awarded 17 Jan 2023

Interferon Beta-1a (Rebif®)

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Edinburgh
£2,103,736
Awarded 20 Jul 2022

Cladribine (Mavenclad®)

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Edinburgh
£33,929,616
Awarded 20 Jul 2022

NP91618d Interferon Beta-1a (Rebif®)

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Edinburgh
£210,374
Awarded 4 Jul 2022

NP91617b Cladribine (Mavenclad®)

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Edinburgh
£2,827,468
Awarded 4 Jul 2022

NHS Framework for Midlands and East, Branded Medicines – Tranche A and Annual

The NHS Commissioning Board (operating under the name of NHS England)
Runcorn
Not specified
Awarded 7 Feb 2022

NHS Framework for the North of England, Branded Medicine

NHS England
Runcorn
£238,913,892
Awarded 7 Feb 2022
Ends 29 Feb 2024

NHS Framework for the North of England, Branded Medicine

The NHS Commissioning Board (operating under the name of NHS England)
Runcorn
Not specified
Awarded 7 Feb 2022

Interferon beta-1 a zur subkutanen Anwendung

AOK Nordwest – Die Gesundheitskasse
DE
Not specified
Awarded 6 Dec 2021

Know when Merck Serono Limited's contracts come up for renewal

Business predicts when each of these contracts is due to be re-tendered, follows Merck Serono Limited for you, and alerts you the moment a renewal goes live, so you can bid before the incumbent locks it in again.

Page 1 of 2

Why track Merck Serono Limited?

Merck Serono Limited is an active supplier to UK public sector buyers. Their contract history is one of the clearest guides to where the work is: which authorities they serve, what those contracts are worth, and, most usefully, when each contract is due to end. A contract nearing its end date is an opportunity, because the buyer will usually run the work again.

How renewal tracking works

We aggregate Merck Serono Limited's award notices from 600+ UK and Irish sources and read the end date on each contract. From those dates, Business predicts when each contract is likely to be re-tendered and, if you follow the supplier, alerts you the moment a matching tender goes live. That head start lets you speak to the buyer and prepare a bid before the incumbent is confirmed again.

What you can do here

  • Review the full history. Every contract Merck Serono Limited has won, with the buyer, value and dates for each.
  • Spot upcoming renewals. Contracts approaching their end date are the ones most likely to reopen.
  • Track and get alerted. Follow Merck Serono Limited and be notified when their contracts come up again (Business).
  • Benchmark and target. See which buyers rely on them and at what value, then focus where you can win.

Frequently asked questions

Where does this data come from?

Official UK and Irish contract award notices, aggregated from 600+ sources and updated daily.

Is the contract history free?

Yes. The full award history, values and buyers are free to browse. Predicted renewal dates, following a supplier and renewal alerts are part of our Business plans.

How do you predict renewals?

From the end dates and durations recorded on awarded contracts. A contract at or near its end date is a strong candidate to return to the market.